BRAF-话题@MedSci

#BRAF#

112篇内容 | 3440人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1355034, encodeId=76db1355034ef, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, objectType=article, longId=218646, objectId=e1fc218646bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1fc218646bf, replyNumber=0, likeNumber=90, createdTime=2021-10-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1fc218646bf, moduleTitle=J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1fc218646bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355033, encodeId=b0f11355033db, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clin Cancer Res：3期coBRIM研究| 威罗非尼+帕博西尼治疗BRAFV600+ 晚期黑色素瘤的长期随访结果, objectType=article, longId=218363, objectId=b482218363b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b482218363b0, replyNumber=0, likeNumber=98, createdTime=2021-10-12, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b482218363b0, moduleTitle=Clin Cancer Res：3期coBRIM研究| 威罗非尼+帕博西尼治疗BRAFV600+ 晚期黑色素瘤的长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b482218363b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355032, encodeId=f7db13550329b, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新, objectType=article, longId=217037, objectId=f9ca21e03751, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9ca21e03751, replyNumber=0, likeNumber=73, createdTime=2021-09-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9ca21e03751, moduleTitle=J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9ca21e03751)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355031, encodeId=120113550318a, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, objectType=article, longId=214664, objectId=c24a214664ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c24a214664ad, replyNumber=0, likeNumber=109, createdTime=2021-07-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c24a214664ad, moduleTitle=Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c24a214664ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355030, encodeId=c105135503078, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, objectType=article, longId=213315, objectId=46ab21331526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46ab21331526, replyNumber=0, likeNumber=77, createdTime=2021-06-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46ab21331526, moduleTitle=Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=46ab21331526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355029, encodeId=01bb1355029d8, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, objectType=article, longId=209533, objectId=155e209533de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=155e209533de, replyNumber=0, likeNumber=91, createdTime=2021-04-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=155e209533de, moduleTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=155e209533de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355028, encodeId=e71d135502866, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物, objectType=article, longId=207182, objectId=7bde20e182c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bde20e182c5, replyNumber=0, likeNumber=72, createdTime=2021-02-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bde20e182c5, moduleTitle=Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bde20e182c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355027, encodeId=76d9135502e7a, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, objectType=article, longId=206683, objectId=000c20668335, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=000c20668335, replyNumber=0, likeNumber=84, createdTime=2021-02-04, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=000c20668335, moduleTitle=Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=000c20668335)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355026, encodeId=a4971355026e8, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, objectType=article, longId=206376, objectId=d9952063e6c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9952063e6c2, replyNumber=0, likeNumber=67, createdTime=2021-01-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9952063e6c2, moduleTitle=Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9952063e6c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355025, encodeId=50771355025b2, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=J Clin Oncol：Encorafenib+西妥昔单抗，BRAF V600E突变型转移性结直肠癌患者的新选择！, objectType=article, longId=206364, objectId=b9a1206364ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9a1206364ab, replyNumber=0, likeNumber=64, createdTime=2021-01-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9a1206364ab, moduleTitle=J Clin Oncol：Encorafenib+西妥昔单抗，BRAF V600E突变型转移性结直肠癌患者的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9a1206364ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355024, encodeId=be951355024d5, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, objectType=article, longId=203872, objectId=e95e2038e2f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e95e2038e2f3, replyNumber=0, likeNumber=78, createdTime=2020-12-01, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e95e2038e2f3, moduleTitle=NICE支持Braftovi治疗BRAF阳性转移性结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e95e2038e2f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355023, encodeId=d7f2135502349, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Br J Cancer：BRAF V600E突变型结直肠癌患者的耐药性相关研究, objectType=article, longId=203687, objectId=cac520368eb0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cac520368eb0, replyNumber=0, likeNumber=92, createdTime=2020-11-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cac520368eb0, moduleTitle=Br J Cancer：BRAF V600E突变型结直肠癌患者的耐药性相关研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cac520368eb0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355022, encodeId=16f21355022ef, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, objectType=article, longId=201779, objectId=f6f5201e7983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6f5201e7983, replyNumber=0, likeNumber=66, createdTime=2020-10-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6f5201e7983, moduleTitle=Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6f5201e7983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355021, encodeId=64d113550212d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, objectType=article, longId=200218, objectId=b6bb200218dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6bb200218dc, replyNumber=0, likeNumber=52, createdTime=2020-09-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6bb200218dc, moduleTitle=NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6bb200218dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355020, encodeId=3528135502068, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, objectType=article, longId=200028, objectId=1381200028b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1381200028b8, replyNumber=0, likeNumber=0, createdTime=2020-08-30, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1381200028b8, moduleTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1381200028b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355019, encodeId=6b531355019e7, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet oncol：达拉非尼联合曲美替尼治疗BRAF V600E突变的胆管癌, objectType=article, longId=199739, objectId=ef2c199e3957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef2c199e3957, replyNumber=0, likeNumber=77, createdTime=2020-08-22, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef2c199e3957, moduleTitle=Lancet oncol：达拉非尼联合曲美替尼治疗BRAF V600E突变的胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef2c199e3957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355018, encodeId=d89e135501873, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, objectType=article, longId=195816, objectId=65141958168d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65141958168d, replyNumber=0, likeNumber=97, createdTime=2020-06-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65141958168d, moduleTitle=Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65141958168d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355017, encodeId=c9dc135501e9d, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, objectType=article, longId=195394, objectId=51fd195394e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51fd195394e1, replyNumber=0, likeNumber=93, createdTime=2020-06-07, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51fd195394e1, moduleTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51fd195394e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355016, encodeId=bd44135501637, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）, objectType=article, longId=193346, objectId=688d193346bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688d193346bb, replyNumber=0, likeNumber=97, createdTime=2020-05-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688d193346bb, moduleTitle=AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=688d193346bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1355015, encodeId=5e2b1355015c7, content=<a href='/topic/show?id=6de63659ed' target=_blank style='color:#2F92EE;'>#BRAF#</a>, objectTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, objectType=article, longId=191946, objectId=1e43191946c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e43191946c0, replyNumber=0, likeNumber=66, createdTime=2020-04-11, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e43191946c0, moduleTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e43191946c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BRAF

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Immunother Cancer：黑素瘤脑转移(MBMs)患者一线BRAF- MEKi耐药后使用ipilimumab- nivolumab治疗效果差

2021-10-17

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clin Cancer Res：3期coBRIM研究| 威罗非尼+帕博西尼治疗BRAFV600+ 晚期黑色素瘤的长期随访结果

2021-10-12

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Thorac Oncol：达拉非尼+曲美替尼治疗转移性BRAF V600E突变非小细胞肺癌的疗效：5年生存结果更新

2021-09-15

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clin Cancer Res：Palbociclib+Vemurafenib治疗BRAF突变型转移性黑色素瘤

2021-07-24

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clin Cancer Res: 考比替尼（cobimetinib）+ 维莫非尼（vemurafenib）对比安慰剂+ 维莫非尼（vemurafenib）治疗BRAF V600突变阳性转移性黑色素瘤的疗效和安全性: coBRIM研究5年长期随访结果

2021-06-28

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元

2021-04-05

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet oncol：BRAFv600突变ctDNA可作为黑色素瘤靶向治疗预后的独立预测生物标志物

2021-02-18

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Br J Cancer：倾向匹配生存分析揭示在携带BRAFV600突变的晚期黑色素瘤患者中抗PD-1单药治疗优于BRAF/MEK抑制剂治疗

2021-02-04

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Eur J Cancer：BRAF和MEK抑制剂联合治疗亚洲晚期黑色素瘤患者的疗效

2021-01-30

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

J Clin Oncol：Encorafenib+西妥昔单抗，BRAF V600E突变型转移性结直肠癌患者的新选择！

2021-01-30

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NICE支持Braftovi治疗BRAF阳性转移性结直肠癌

2020-12-01

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Br J Cancer：BRAF V600E突变型结直肠癌患者的耐药性相关研究

2020-11-25

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Nat Med: 联合PD-1、BRAF和MEK抑制剂治疗晚期BRAF突变型黑色素瘤

2020-10-08

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

NEJM：Dabrafenib联合Trametinib 治疗III期黑色素瘤患者长期生存数据喜人

2020-09-05

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性

2020-08-30

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet oncol：达拉非尼联合曲美替尼治疗BRAF V600E突变的胆管癌

2020-08-22

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

Lancet：Atezolizumab-Vemurafenib-Cobimetinib一线治疗晚期BRAF V600突变阳性黑色素瘤

2020-06-15

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌

2020-06-07

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）

2020-05-03

zhaojie88 (审核中...)

前往app查看评论内容

#BRAF#

辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌

2020-04-11

科室
- - 订阅+
  - 更多科室
工具
服务